Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients

Kaohsiung Journal of Medical Sciences

Volumn 28, Issue 2, 2012, Pages 86-93

  Hsieh, Ming Yen ^a,b   Dai, Chia Yen ^a,b   Lee, Li Po ^a   Huang, Jee Fu ^b,c   Chuang, Wan Long ^a,b   Hou, Nai Jen ^c   Lin, Zu Yau ^a,b   Chen, Shinn Cherng ^a,b   Hsieh, Ming Yuh ^a,b   Wang, Liang Yen ^a,b   Chang, Wen Yu ^a,b   Yu, Ming Lung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

Antinuclear antibody (ANA); Hepatitis C virus; Peginterferon; Ribavirin; Sustained virological response (SVR)

Indexed keywords

ANTINUCLEAR ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANEMIA; ANOREXIA; ANTIBODY TITER; ANXIETY DISORDER; ARTICLE; ASTHENIA; CHILL; CLINICAL PRACTICE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; GENOTYPE; HAIR LOSS; HEPATITIS C; HUMAN; INJECTION SITE ERYTHEMA; INSOMNIA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PROGNOSIS; PROSPECTIVE STUDY; RASH; SIDE EFFECT; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTOPENIA; THYROID FUNCTION TEST; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; YOUNG ADULT;

EID: 84862786861     PISSN: 1607551X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.kjms.2011.10.031     Document Type: Article

References (39)

1. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
2. R.W. McMurray, and K. Elbourne Hepatitis C virus infection and autoimmunity Semin Arthritis Rheum 26 1997 689 701 (Pubitemid 27118536)
3. B.D. Clifford, D. Donahue, L. Smith, E. Cable, B. Luttig, and M. Manns High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C Hepatology 21 1995 613 619
4. E.P. Lopes, A.E. Silva, H. Sette Junior, R.X. Guimarães, and M.L. Ferraz Autoantibodies before, during and after administration of recombinant interferon-alpha for chronic viral hepatitis Rev Inst Med Trop Sao Paulo 37 1995 455 460 (Pubitemid 26027661)
5. Y. Bayraktar, M. Bayraktar, A. Gurakar, T.I. Hassanein, and D.H. Van Thiel A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases Hepatogastroenterology 44 1997 417 425 (Pubitemid 27171051)
6. L.J. Yee, P. Kelleher, R.D. Goldin, S. Marshall, H.C. Thomas, and A. Alberti Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance J Viral Hepat 11 2004 459 464 (Pubitemid 39336229)
7. F. Cassani, M. Cataleta, P. Valentini, P. Muratori, F. Giostra, and R. Francesconi Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile Hepatology 26 1997 561 566 (Pubitemid 27392344)
8. P. Muratori, L. Muratori, M. Guidi, A. Granito, M. Susca, and M. Lenzi Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C Clin Infect Dis 40 2005 501 507 (Pubitemid 40270217)
9. P. Muratori, L. Muratori, G. Verucchi, L. Attard, F.B. Bianchi, and M. Lenzi Non-organ-specific autoantibodies in children with chronic hepatitis C: clinical significance and impact on interferon treatment Clin Infect Dis 37 2003 1320 1326 (Pubitemid 37433627)
10. H.E. Wasmuth, C. Stolte, A. Geier, C.G. Dietrich, C. Gartung, and J. Lorenzen The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C BMC Infect Dis 4 2004 4
11. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Gonales Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
12. D. Zauli, F. Cassani, and F.B. Bianchi Auto-antibodies in hepatitis C Biomed Pharmacother 53 1999 234 241
13. P. Cacoub, C. Renou, E. Rosenthal, P. Cohen, I. Loury, and V. Loustaud-Ratti Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C Medicine (Baltimore) 79 2000 47 56 (Pubitemid 30077736)
14. M.Y. Hsieh, C.Y. Dai, L.P. Lee, J.F. Huang, W.C. Tsai, and N.J. Hou Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C J Clin Pathol 61 2008 333 337
15. C.Y. Dai, W.L. Chuang, W.Y. Chang, S.C. Chen, L.P. Lee, and Z.Y. Lin The prevalence and clinical characteristics of coinfection of SENV-H among Taiwanese chronic hepatitis C patients with combination therapy of high-dose interferon-alfa and ribavirin Antiviral Res 64 2004 47 53
16. C.Y. Dai, W.L. Chuang, W.Y. Chang, S.C. Chen, L.P. Lee, and M.Y. Hsieh Polymorphisms in the interferon-gamma gene at position +874 in patients with chronic hepatitis C treated with high-dose interferon-alpha and ribavirin Antiviral Res 67 2005 93 97
17. W.L. Chuang, C.Y. Dai, W.Y. Chang, L.P. Lee, Z.Y. Lin, and S.C. Chen Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy Antivir Ther 10 2005 125 133
18. C.Y. Dai, W.L. Chuang, W.Y. Chang, S.C. Chen, L.P. Lee, and M.Y. Hsieh Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection J Infect Dis 193 2006 98 101
19. M.L. Yu, C.Y. Dai, J.F. Huang, N.J. Hou, L.P. Lee, and M.Y. Hsieh A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C Gut 56 2007 553 559
20. R.G. Knodell, K.G. Ishak, W.C. Black, T.S. Chen, R. Craig, and N. Kaplowitz Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1 1981 431 435 (Pubitemid 12218164)
21. F. Cassani, F.B. Bianchi, M. Lenzi, U. Volta, and E. Pisi Immunomorphological characterisation of antinuclear antibodies in chronic liver disease J Clin Pathol 38 1985 801 805 (Pubitemid 15015891)
22. J.J. Tsai, W.J. Tsai, J.H. Yen, J.R. Chen, S.F. Lin, and H.W. Liu Malignant pheochromocytoma associated with Jaccoud's-type arthropathy, Raynaud's phenomenon, positive antinuclear antibody and rheumatoid factor Kaohsiung J Med Sci 10 1994 518 521
23. H. Okamoto, H. Tokita, M. Sakamoto, M. Horikita, M. Kojima, and H. Iizuka Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection J Gen Virol 74 Pt 11 1993 2385 2390 (Pubitemid 23332299)
24. NIH Consensus Statement on Management of Hepatitis C: 2002 NIH Consens State Sci Statements 19 2002 1 46
25. S.D. Lee, M.L. Yu, P.N. Cheng, M.Y. Lai, Y.C. Chao, and S.J. Hwang Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan J Viral Hepat 12 2005 283 291
26. M.L. Yu, C.Y. Dai, Z.Y. Lin, L.P. Lee, N.J. Hou, and M.Y. Hsieh A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan Liver Int 26 2006 73 81
27. M.L. Yu, C.Y. Dai, J.F. Huang, C.F. Chiu, Y.H. Yang, and N.J. Hou Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial Hepatology 47 2008 1884 1893
28. T. Poynard, P. Marcellin, S.S. Lee, C. Niederau, G.S. Minuk, and G. Ideo Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352 1998 1426 1432 (Pubitemid 28510876)
29. M.L. Yu, W.L. Chuang, C.Y. Dai, S.C. Chen, Z.Y. Lin, and M.Y. Hsieh Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the quantiplex HCV version 2.0 test J Clin Microbiol 38 2000 2933 2939
30. G.M. Lauer, and B.D. Walker Hepatitis C virus infection N Engl J Med 345 2001 41 52 (Pubitemid 32634271)
31. W.L. Chuang, M.L. Yu, C.Y. Dai, and W.Y. Chang Treatment of chronic hepatitis C in southern Taiwan Intervirology 49 2006 99 106
32. S. Zeuzem, R. Hultcrantz, M. Bourliere, T. Goeser, P. Marcellin, and J. Sanchez-Tapias Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3 J Hepatol 40 2004 993 999 (Pubitemid 38670134)
33. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, and P. Marcellin Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
34. R.H. White, and D.L. Robbins Clinical significance and interpretation of antinuclear antibodies West J Med 147 1987 210 213 (Pubitemid 17125273)
35. A.J. Czaja, and H.A. Carpenter Histological findings in chronic hepatitis C with autoimmune features Hepatology 26 1997 459 466 (Pubitemid 27328326)
36. M.J. Williams, A. Lawson, K.R. Neal, S.D. Ryder, and W.L. Irving Trent HCV Group. Autoantibodies in chronic hepatitis C virus infection and their association with disease profile J Viral Hepat 16 2009 325 331
37. T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 1997 825 832 (Pubitemid 27129209)
38. M.C. Hsieh, M.L. Yu, W.L. Chuang, S.J. Shin, C.Y. Dai, and S.C. Chen Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C Eur J Endocrinol 142 2000 431 437
39. J.F. Huang, W.L. Chuang, C.Y. Dai, S.C. Chen, Z.Y. Lin, and L.P. Lee The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy J Viral Hepat 13 2006 396 401